Hepatic Impairment
19 competing products in clinical development for Hepatic Impairment.
Pipeline by Phase
Phase 118
Phase 1/21
All Products (19)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Quizartinib | Daiichi Sankyo | Phase 1 | Recruiting | 36 |
| Tasurgratinib + Tasurgratinib | Eisai | Phase 1 | Recruiting | 36 |
| DS-3201b | Daiichi Sankyo | Phase 1 | Completed | 29 |
| Quizartinib | Daiichi Sankyo | Phase 1 | Completed | 29 |
| Tivantinib + Tivantinib + Tivantinib + Tivantinib | Daiichi Sankyo | Phase 1 | Completed | 29 |
| Bocidelpar | Astellas Pharma | Phase 1 | Completed | 29 |
| fezolinetant | Astellas Pharma | Phase 1 | Completed | 29 |
| ASP2215 | Astellas Pharma | Phase 1 | Completed | 29 |
| BPN14770 | Shionogi | Phase 1 | Completed | 29 |
| S-217622 | Shionogi | Phase 1 | Completed | 29 |
| Lemborexant | Eisai | Phase 1 | Completed | 29 |
| Lenvatinib | Eisai | Phase 1 | Completed | 29 |
| Lorcaserin | Eisai | Phase 1 | Completed | 29 |
| KW-6356 | Kyowa Kirin | Phase 1 | Completed | 29 |
| Istradefylline | Kyowa Kirin | Phase 1 | Completed | 29 |
| ONO-2745 /CNS 7056 | Ono Pharmaceutical | Phase 1 | Completed | 29 |
| ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results) | Idorsia | Phase 1 | Completed | 23 |
| ITF2357 | Biotrial | Phase 1 | Completed | 19 |
| GB1211 + Placebo | Comac Medical | Phase 1/2 | UNKNOWN | 18 |